基本信息
views: 10
Career Trajectory
Bio
Research
Drug Discovery
We are interested in developing drug leads/candidates for new targets including kinase, phosphate kinase and protein targets identified by UNC faculty and external investigators. We have successfully used the structure- and/or ligand-based drug design approaches to deliver compounds to clinic (MerTK inhibitors) or licensing (IDH1 inhibitor, co-developed with NCATs). We will continue to apply the similar approaches for drug discovery towards new targets.
Synthetic Methodology Development
Heterocyclic compounds are widely used in drug discovery as key pharmacophores. However, some are not readily available and are difficult to prepare in the variety and quantities needed for structure-activity relationship studies. We are currently interested in developing short, effective and robust synthetic routes for these heterocycles.
Research Interests
Papers共 174 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Xingyao Li, Regan B. Kirkpatrick,Xiaodong Wang, Charles J. Tucker, Anuj Shukla,Henning J. Jessen,Huanchen Wang,Stephen B. Shears,Chunfang Gu
Cell Reportsno. 6 (2024): 114316-114316
JOURNAL OF MEDICINAL CHEMISTRYno. 7 (2024): 5866-5882
Nature Communicationsno. 1 (2024): 1-19
biorxiv(2024)
Nature communicationsno. 1 (2024): 5292-5292
Journal of medicinal chemistryno. 7 (2024): 5866-5882
Yan Kai Zhong, Xixi Tan,Xiaodong Wang, Jun Jiang, Kai Shu, Haiyuan Chen,Hao Zhang,Zuoyun Wang,Lei Zhang, Chunming Guo,Hongfeng Liang,Wei Yu
Journal of Biochemical and Molecular Toxicology (2023)
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn